Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
45
BLCO.TO Quote, Financials, Valuation and Earnings
Last price:
$22.20
Seasonality move
:
5.47%
Day range:
$22.06 - $23.64
52-week range:
$14.56 - $26.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.13x
P/B ratio:
0.88x
Volume:
16.2K
Avg. volume:
2.1K
1-year change:
-14.42%
Market cap:
$7.9B
Revenue:
$6.6B
EPS (TTM):
-$1.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLCO.TO
Bausch + Lomb Corp.
|
$1.7B | $0.10 | 6.36% | 1360.48% | $24.48 |
|
BHC.TO
Bausch Health Cos., Inc.
|
$3.4B | $0.97 | 6.92% | 375.64% | $6.98 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLCO.TO
Bausch + Lomb Corp.
|
$22.20 | $24.48 | $7.9B | -- | $0.00 | 0% | 1.13x |
|
BHC.TO
Bausch Health Cos., Inc.
|
$9.49 | $6.98 | $3.5B | 7.11x | $0.00 | 0% | 0.25x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLCO.TO
Bausch + Lomb Corp.
|
43.5% | 2.067 | 91.5% | 0.76x |
|
BHC.TO
Bausch Health Cos., Inc.
|
102.76% | 0.758 | 636.35% | 0.78x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLCO.TO
Bausch + Lomb Corp.
|
$968.3M | $110.2M | -2.64% | -4.61% | 6.25% | $90.1M |
|
BHC.TO
Bausch Health Cos., Inc.
|
$2.3B | $987.5M | 1.47% | -- | 26.74% | $433.6M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Bausch + Lomb Corp. vs. Competitors
-
Which has Higher Returns BLCO.TO or BHC.TO?
Bausch Health Cos., Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of 6.75%. Bausch + Lomb Corp.'s return on equity of -4.61% beat Bausch Health Cos., Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B -
What do Analysts Say About BLCO.TO or BHC.TO?
Bausch + Lomb Corp. has a consensus price target of $24.48, signalling upside risk potential of 10.26%. On the other hand Bausch Health Cos., Inc. has an analysts' consensus of $6.98 which suggests that it could fall by -26.41%. Given that Bausch + Lomb Corp. has higher upside potential than Bausch Health Cos., Inc., analysts believe Bausch + Lomb Corp. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLCO.TOBausch + Lomb Corp.4 8 0 BHC.TOBausch Health Cos., Inc.0 7 0 -
Is BLCO.TO or BHC.TO More Risky?
Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bausch Health Cos., Inc. has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.787%.
-
Which is a Better Dividend Stock BLCO.TO or BHC.TO?
Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bausch Health Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Bausch Health Cos., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLCO.TO or BHC.TO?
Bausch + Lomb Corp. quarterly revenues are $1.8B, which are smaller than Bausch Health Cos., Inc. quarterly revenues of $3.7B. Bausch + Lomb Corp.'s net income of -$34.4M is lower than Bausch Health Cos., Inc.'s net income of $249.3M. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Bausch Health Cos., Inc.'s PE ratio is 7.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.13x versus 0.25x for Bausch Health Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M
-
Which has Higher Returns BLCO.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.61% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About BLCO.TO or COOL.CX?
Bausch + Lomb Corp. has a consensus price target of $24.48, signalling upside risk potential of 10.26%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch + Lomb Corp. has higher upside potential than Core One Labs, Inc., analysts believe Bausch + Lomb Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLCO.TOBausch + Lomb Corp.4 8 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is BLCO.TO or COOL.CX More Risky?
Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock BLCO.TO or COOL.CX?
Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLCO.TO or COOL.CX?
Bausch + Lomb Corp. quarterly revenues are $1.8B, which are larger than Core One Labs, Inc. quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$34.4M is higher than Core One Labs, Inc.'s net income of --. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.13x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns BLCO.TO or CURE.X.CX?
Biocure Technology has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.61% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About BLCO.TO or CURE.X.CX?
Bausch + Lomb Corp. has a consensus price target of $24.48, signalling upside risk potential of 10.26%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch + Lomb Corp. has higher upside potential than Biocure Technology, analysts believe Bausch + Lomb Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings BLCO.TOBausch + Lomb Corp.4 8 0 CURE.X.CXBiocure Technology0 0 0 -
Is BLCO.TO or CURE.X.CX More Risky?
Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BLCO.TO or CURE.X.CX?
Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLCO.TO or CURE.X.CX?
Bausch + Lomb Corp. quarterly revenues are $1.8B, which are larger than Biocure Technology quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$34.4M is higher than Biocure Technology's net income of --. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.13x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns BLCO.TO or HEAL.CX?
has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.61% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B HEAL.CX-- -- -- -
What do Analysts Say About BLCO.TO or HEAL.CX?
Bausch + Lomb Corp. has a consensus price target of $24.48, signalling upside risk potential of 10.26%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch + Lomb Corp. has higher upside potential than , analysts believe Bausch + Lomb Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings BLCO.TOBausch + Lomb Corp.4 8 0 HEAL.CX0 0 0 -
Is BLCO.TO or HEAL.CX More Risky?
Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BLCO.TO or HEAL.CX?
Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLCO.TO or HEAL.CX?
Bausch + Lomb Corp. quarterly revenues are $1.8B, which are larger than quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$34.4M is higher than 's net income of --. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.13x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M HEAL.CX-- -- -- --
-
Which has Higher Returns BLCO.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -1.95% compared to Bausch + Lomb Corp.'s net margin of --. Bausch + Lomb Corp.'s return on equity of -4.61% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About BLCO.TO or NSHS.CX?
Bausch + Lomb Corp. has a consensus price target of $24.48, signalling upside risk potential of 10.26%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch + Lomb Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Bausch + Lomb Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLCO.TOBausch + Lomb Corp.4 8 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is BLCO.TO or NSHS.CX More Risky?
Bausch + Lomb Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock BLCO.TO or NSHS.CX?
Bausch + Lomb Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch + Lomb Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLCO.TO or NSHS.CX?
Bausch + Lomb Corp. quarterly revenues are $1.8B, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Bausch + Lomb Corp.'s net income of -$34.4M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Bausch + Lomb Corp.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch + Lomb Corp. is 1.13x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
